No one should face hereditary cancer alone.

Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.

Toggle Menu

Tumor Testing

There are many options for treating hereditary cancers. Choice of treatment can be personalized based on cancer type, stage and genetics.

Tumor tests for prognosis

All cancers have different mutations. Genomic testing can use these differences to predict how aggressively a cancer may behave and whether or not it’s likely to recur. Most frequently used for breast and prostate cancer, prognostic tumor tests helps doctors and patients decide how to treat a cancer. Insurance often covers the cost of these tests, especially those that are included in the National Comprehensive Cancer Network (NCCN) Guidelines.

Breast cancer tumor prognostic tests

Some examples of the most commonly used prognostic tests for breast cancer are:

  • Oncotype Dx™ estimates the risk of recurrence after a diagnosis of early-stage ER-positive disease. Test results are mainly used to help make decisions about whether chemotherapy should be added to a person’s treatment.
  • Breast Cancer Index™ may help to make decisions about the length of a woman’s endocrine therapy.
  • MammaPrint™ predicts the risk of recurrence for early-stage breast cancer.
  • Prosigna™ is used to predict if a breast cancer will metastasize.

Prostate cancer tumor prognostic tests

NCCN Guidelines for prostate cancer include discussion of several different tests that can predict the aggressiveness and risk for recurrence of a tumor. More aggressive treatment may be offered to men with an aggressive cancer and a higher likelihood of recurrence. These tests include:

  • Decipher® looks at genes within the tumor to predict the likelihood that the cancer will metastasize within 5 years.
  • Prolaris® looks at genes within the tumor to determine how aggressive the cancer is and predicts riks of recurrence, metastasis and death.
  • OncotypeDX® Genomic Prostate Score™ Test measures the aggressiveness of prostate tumors and predicts the risk for metastasis and death at 10 years.
  • Promark® measures tumor proteins to provide a personalized prediction that the cancer can be managed without aggressive treatment or an indication that aggressive therapy may be appropriate.

Updated 04/26/2018

FORCE:Facing Our Risk of Cancer Empowered